Denosumab and muscle performance

Osteoporos Int. 2023 Jan;34(1):211-212. doi: 10.1007/s00198-022-06587-5. Epub 2022 Nov 15.

Authors

Tim Rolvien¹, Tobias Rupp², André Strahl³, Michael Amling²

Affiliations

¹ Department of Trauma and Orthopaedic Surgery, Division of Orthopaedics, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. t.rolvien@uke.de.
² Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ Department of Trauma and Orthopaedic Surgery, Division of Orthopaedics, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bone Density Conservation Agents* / adverse effects
Denosumab* / pharmacology
Denosumab* / therapeutic use
Humans
Muscles
RANK Ligand

Substances

Denosumab
Bone Density Conservation Agents
RANK Ligand